Cellular Biomedicine Group to Present at the Cantor Fitzgerald Global Healthcare Conference
September 14, 2017 08:30 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
Cellular Biomedicine Group Reports Second Quarter and First Half 2017 Financial Results and Business Highlights
August 08, 2017 16:31 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
Cellular Biomedicine Group (CBMG) Appoints Dr. Xia Meng as Chief Operating Officer to Lead Commercialization of the Company’s CAR-T and Stem Cell Products
June 26, 2017 07:28 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
Cellular Biomedicine Group Appoints Michael A. Caligiuri, MD as Chair of External Advisory Board
June 20, 2017 06:00 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
Cellular Biomedicine Group（CBMG）宣布股票回购计划
June 02, 2017 13:25 ET
|
Cellular Biomedicine Group Inc.
中国上海市与加州库伯提诺市, June 03, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc.（纳斯达克代码：CBMG，以及称为“纳斯达克”或“公司”）是一家临床分期生物制药公司，它从事于癌症有效免疫疗法与退化性疾病干细胞疗法的研究。该公司宣布，公司董事会（“董事会”）已根据1934 年《证券交易法》第 10b5-1 条和第...
Cellular Biomedicine Group (CBMG) Announces Stock Repurchase Program
June 01, 2017 06:00 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
Cellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody” in Conjunction with 2017 ASCO Annual Meeting
May 19, 2017 08:28 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., May 19, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
Cellular Biomedicine Group (CBMG) Announces the Addition of a Second Clinical Site in the Expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I Clinical Trial for Its CARD-1 Trial in Patients with Non-Hodgkin Lymphoma (NHL)
May 15, 2017 06:22 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
Cellular Biomedicine Group Reports First Quarter 2017 Financial Results and Provides Business Highlights
May 08, 2017 16:01 ET
|
Cellular Biomedicine Group Inc.
Commenced Phase I Trial (CALL-1) for C-CAR011 in adult patients with relapsed or refractory B-cell Acute Lymphoblastic Leukemia (ALL) in ChinaStrategic partnership with GE Healthcare Life Sciences...
Cellular Biomedicine Group Announces Results of 2017 Annual Meeting of Stockholders
May 01, 2017 16:01 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), clinical-stage biopharmaceutical firm engaged in the...